Investor's Business Daily on MSN2h
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy ...
Catalyst Pharmaceuticals stock hits all-time high of $24.44
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares soared to an all-time high this week, reaching a peak of $24.44. According ...
Catalyst Pharmaceuticals Posts Corporate Presentation in Recent 8-K Filing
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently disclosed in an 8-K filing with the Securities and Exchange Commission on January 13, 2025, that the company has posted a corporate presentation ...
Yahoo Finance14d
Santhera launches DMD therapy in the UK following NICE nod
Swiss biotech Santhera Pharmaceuticals has started launch preparations for its Duchenne muscular dystrophy (DMD) drug Agamree (vamorolone) in the UK, following a recommendation from England’s price ...
The Pharma Letter15d
Truveta Genome Project aims to create world’s largest genetic database
US health systems and Regeneron Genetics Center launch the Truveta Genome Project, a $320M initiative to sequence up to 10M exomes. Focused on diversity, the project aims to link genetic data with ...
TMCnet15d
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
This follows confirmation that no appeals were received against the Final Draft Guidance (FDG) recommendation announced on December 10, 2024. Following this, Santhera has already started launch ...
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
(SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently ...
Idorsia Pharmaceuticals Ltd: Idorsia presents at J.P. Morgan Healthcare Conference 2025 - fighting to create value for all stakeholders
Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand Allschwil, Switzerland - January 15 ...
Pharmabiz16d
Santhera gets positive recommendation from Scottish Medicines Consortium for use of Agamree to treat Duchenne muscular dystrophy
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company, announces that the Scottish Medicines Consortium (SMC) has published recommendations that Agamree (vamorolone) is accepted for use ...
WebMD16d
Duchenne Muscular Dystrophy
The drugs also can help your child’s heart and lungs work better. A unique type of steroid drug, vamorolone (Agamree), is also available for kids and teens with DMD. It helps reduce inflammation ...
Nasdaq17d
Santhera's AGAMREE Gets Positive NHS Scotland Nod For Duchenne Muscular Dystrophy Treatment
(RTTNews) - Santhera Pharmaceuticals said that it received positive recommendation from the Scottish Medicines Consortium for use of AGAMREE (Vamorolone) within NHS Scotland for the treatment of ...